Vera Therapeutics, Inc.

Vera Therapeutics, Inc. (VERA) priced its initial public offering on May 17, 2021 at $11.00 per share, below its $14.00–$16.00 range, raising $47.9M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $225.3M. Jefferies was lead-left underwriter, joined by TD Cowen and Evercore ISI. Cooley advised the company and Goodwin Procter advised the underwriters.

Vera Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for serious immunological diseases. Its lead candidate, atacicept, blocks BLyS and APRIL and is in a Phase 2b trial for immunoglobulin A nephropathy (IgAN), a progressive autoimmune kidney disease.

Status

IPO

Ticker

VERA

Exchange

Nasdaq Global Market

Priced

May 17, 2021

IPO price

$11.00

Price range

$14.00–$16.00

Raised

$47.9M

Market cap at IPO price

$225.3M

First filed

Apr 23, 2021

Underwriters

Jefferies, TD Cowen and Evercore ISI

Company counsel

Cooley

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.